DK200600643A - Piscirickettsia Salmonis-antigener og anvendelse deraf - Google Patents
Piscirickettsia Salmonis-antigener og anvendelse deraf Download PDFInfo
- Publication number
- DK200600643A DK200600643A DK200600643A DKPA200600643A DK200600643A DK 200600643 A DK200600643 A DK 200600643A DK 200600643 A DK200600643 A DK 200600643A DK PA200600643 A DKPA200600643 A DK PA200600643A DK 200600643 A DK200600643 A DK 200600643A
- Authority
- DK
- Denmark
- Prior art keywords
- present
- discloses
- srs
- antigens
- piscirickettsia salmonis
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract description 4
- 102000036639 antigens Human genes 0.000 title abstract description 4
- 108091007433 antigens Proteins 0.000 title abstract description 4
- 241000192126 Piscirickettsia salmonis Species 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 10
- 241000251468 Actinopterygii Species 0.000 abstract description 8
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 102000039446 nucleic acids Human genes 0.000 abstract description 7
- 108020004707 nucleic acids Proteins 0.000 abstract description 7
- 150000007523 nucleic acids Chemical class 0.000 abstract description 7
- 241000606651 Rickettsiales Species 0.000 abstract description 3
- 241000277331 Salmonidae Species 0.000 abstract description 2
- 206010040047 Sepsis Diseases 0.000 abstract description 2
- 244000052769 pathogen Species 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 208000013223 septicemia Diseases 0.000 abstract description 2
- -1 e.g. Proteins 0.000 abstract 2
- 241001148129 Yersinia ruckeri Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 235000019688 fish Nutrition 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000277263 Salmo Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001327682 Oncorhynchus mykiss irideus Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229910001710 laterite Inorganic materials 0.000 description 1
- 239000011504 laterite Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Paper (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
Description
WIHTKPAV: 1, Isoleret ftp4S<<pn#læin Pir prrftttfr niiraffe én af filgendfe C«) iminiOiymsak¥iPStri Pffigi SIQ IP NO; 4 dkr Omfettfer' en konservativ imerosfriiybiliytiéR· $g (!>) en arafeosyrasekverB. tler har mindst 70% identlef mod emirmsyresrakarensen ifølge SEQ ID NO; 2 eller 4, 2, Isntenet antlgent fragment af fep4S~pr®teinet tfelge krav 1.
3, tskomfemantiiroiypeptld der ømføttet aramesyregekwrwen af ®p4S-proteinet iféigekrav I efter det antigene fragment ifølge krav 2,- 4, ftekoméføaniip«iypeptid ifølge krav 3, hMIket poiypepfd er et klmaert protein.
5, Antistof mm er fremstillet med mindst ét af føl#ender(a> iaoleret^p4S'*pro'eln tfslge krav ij (l>| Isoleret aåtfgent fragment Ifølge- krav 2; (c) refeomWnént solypeptid Ifølge krav 3 og(d| rokemdltiant poiy peptid Ifølge krav 4, å. issieret: eller rekemdlnaot nukleinsyre der keder fer mindst ét af følgende; (a) laterit Qp4S-protein Ifølge krav ij(d| isfeerof astlgeot fragment ifølge- krav l; (e| «kemdlnant p-oiy peptid Ifølge krav 3 og(d| rekarnpfflint pDlyptpiiil ifølge krav 4.
?, ^ykleinayre ifølge krav i, hvilken eekitlnsyre droftiterefi nokieolldsekvens. der ervalgt fra proppen tetiende if SEQ ID NO; i og SEQ ID NO;3, S. ^yfeieinsyre dér hyprldserer til siykleeéldsekvenssn ifølge krav- 7 hvor nukteiesyrenomfatter mindst 12 nykleotiPer.
9., Ekspressionsvektor der omfatter nukleinsyren ifølge et hvilket som helst af kraveneden treniskripéooelle rogyleringssekvens, 10. VasrtPMÉte der enStir eksproselQfisvekipre« ifølge few % 11.. iFsremgøngsmScte tiliiiiiptillhp ^i:^i;:réiiiiH|iiil gøngsmåde ornføtør dysxning øf v«stsceMen ifplg© krøv 10 i et dyrknlngsmedlum hvor lip?fiiél!!!lii!HlWr ddiliillilln|§i% der tøder fpr det rekombinante poppeptidf Pihvqrvad det r^kqrebinenie pøiypeptid frem bringes.
illilll ||r«rRsapQsr^||| ifiigp |pv li|l||drl|pNsæieP|||' 13. Fremoangsmlde ti i epnåek-e af et op re π <«t re kore bi rsent poly pe rstld, hvil k en fremgangsmåde omfatter opr^||nfr|ii!!p!|!!!··· eelf||i|i!|!i|iff|®||!p d |||;ιΐβ............
<- omgangs '\v\ V ' ,w ||
14. || lllllpet r^iieig»oiibiin^dllÉifoSορκι!Ι|||||Ι'!|#β®π®^Ρ^οπ lige kriv j|||||P, 13, II
15. ftekombiswt YersM& rac^ert-æfie der omfatter nukleinsyren ifølge et hvilket som......teist af kravene 6-8, IIjII IfckomibllllllBlpfpfe IS, :wi d®poKieri«§snr. IMG P-22044.
i|||, I IJlllsMa mctol celle med ecCMPeterierlepnr,. IMG F2Bll„ 18. Vaccine aer omfatter re In ast ét af følgende; (a) isoleret ifølge krav l; II |||||| isoleret aedgent fragment Ifelge krav 2; II llllli rétøm bi nglijiliv^li^lii|j^jfcJiiiliillllliililii;;;.
11' |||||| mfc© m te i π;® π ||||p Sy ρ^||||!| | ill I VoctfllllllBiBliir h|||lnsyr|| ..||1|::: i|||l 11 ^c^||i||!iej|br |||i rekonfiildhte yiHiiHIHfterillpif ifeigillp^ IS plliil i|lf...........11 ||1,|| Il Iftøte;-e Nr^i ^illb NyilliiÉin liiti fol iliidiliiliiiiilbllifcfegrr-ce ί;ΙϋίΙ^Ιϋ: eiillfiiiiilirl .......
22, 11; fcrpf 17, ;J||f |§§ Il VaallllJillll^ 2||||ec de?ii|^|ip!|||||||^||p^f aepnp||lpr ff tektill, ||1 24, hr# 2|| Ipken jilililipiÉ|Mfellrllililr en
Ywsnm med BCCM-deponerlngsnr. IMG fr-22044 hvor den ander» Kers/røa .....f^ciiilillllpr ei:i:Sli|e||i, || 25, Vaccine ifoige er hvilket som h®|*t af kravene ΐβ-24» hvilken voco'ne yderligere omfatter et l||igei!|ler dlljllillllÉllllfcrjlPllIkroie clililllBlllll 26, Vaccine ifølge krav 25 hvor det antigen der er opnået fra IPN-vlrosset, er valgt fra gris ppen bestående af VP2-var- proteinet ......Ifrfilllllfctge et ellllsiB hlHsi kravene 18-2¾ llf|§§t vaccine yderligere ·1ΐριρ:': ©mfBCtePiHii ¥P2~vi^d||l&t oflll^-prOteiniet fra liN|§|pt panæasnekrøse (Mill-virus 28. Vaccine ifølge krav 27 hvor VPl-var-prl·/.«..·· «..* ..·· . l· ·..·_*. ·,. -.· i 5 <.m·'. ‘‘.«.frv 1^ ;^ll^l:^i^por|i:riÉg^^r|||!|H EM og V||~prøteiriei l||||iiet fri en illilÉllHlret: ΙβΡί^1&Λ·ι|®ΐΙ#ί ||;CN-depon#rlrs§snll ihem 2§(1ΐ||ΐΐΐ llillllllteed .....Iflhvor ^2»vamprøtej|it ifftø pastors-celle, BCCM-deponerirtgsnr. IH EM 2QH7Q., og VP3-proteinet er opnået fri entransformeret pasiorfe-ce«e. BCO-1 - deponeringsnr. IH EM 20Q73- 3Q, Vaccine [følges ot hvilket som helst: af vd^nlN^fefe^li omfatter et antigen der er opnået fra ^ergtiprsgilllfc^ 31, r tl· ix'S" frfreis® af fisk mod salmonid rickettsial septicemia, hvilken fremgangsmåde omfatter administration tf fisken af vaccinen ifølge et hvisker som helst afkravene løflilllllilllllll.
32, Fremgangsmåde ifølge krav 31 hvor fisken er ©n teleost, 33, * “emga ις-m Ve fo go * m** 32 hvor teieosten er en laksefisk.
34, fremgangsmåde th beskyttelse af fisk mod satmmtø rickettsial septkmus ogInfektiost pancreasnekmse, hvilken fremgangsmåde omfatter administration til fisken af liBillililpSfe et livlllii låfelfeist: af kravene |l||l||||l:: 35, Fremgangsmåde Ifølge krav 34 hvor fisken er en laksefisk, 3$. Fremgangsmad« ifølge krav 33 eter 35 hvor laksefisken er valgt fra gruppenbestående af en Salmo sefer i atlantisk laks), en OtKorhynchys Mwt<A fcøhøtaks) og enOncorh^cfeu« mytess (regnbue®rred).
37. Vaoone til beskyttelse mod et Intracellatert patogen fil anvendelse i et ikte-humant dyr, hvilken vaccine ørnfatter an rekørnblnant enterisk bakterie der koder før ét;!!|erf!|!!|nt;sl!!!l|p: dit Inferac^liSljfeni1 P::'3B,. jllllllllifcginlllllilfe v' 37''ril!liÉI!!!iiiP%n^^lsNæ b ':ll ΐη!ί!!!!Μίί:Ρ.............
39. Vaccine ifølge krav 38 hvor det ikte-hu mane dyr er en ff sk.
lllllllilllccine :||||;||rav 39 pipr ^|r|pea«tl|iflot l!ii!||i|||cfene ll|j||iiil;rav 40 !||©r 4§rf ptemhlrsnte i||e||ii®li|pHeliiliiiiiilihvefeal, 1111111 |||ll:: ftemiang|f§§pe ti i j||€||st^; jiilipipllle· ............... admlnlst|§|§p ti §|§ af |||||| ............llréÉi..................
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE20030743 | 2003-10-07 | ||
| IE20030743 | 2003-10-07 | ||
| IB2004003339 | 2004-10-01 | ||
| PCT/IB2004/003339 WO2005035558A2 (en) | 2003-10-07 | 2004-10-01 | Piscirickettsia salmonis antigens and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK200600643A true DK200600643A (da) | 2006-05-05 |
| DK177141B1 DK177141B1 (da) | 2012-02-06 |
Family
ID=34430665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DKPA200600643A DK177141B1 (da) | 2003-10-07 | 2006-05-05 | Piscirickettsia Salmonis-antigener og anvendelse deraf |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7754223B2 (da) |
| EP (1) | EP1670818B1 (da) |
| AT (1) | ATE473236T1 (da) |
| AU (1) | AU2004279610B2 (da) |
| CA (1) | CA2541464C (da) |
| DE (1) | DE602004028029D1 (da) |
| DK (1) | DK177141B1 (da) |
| NO (1) | NO341223B1 (da) |
| WO (1) | WO2005035558A2 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005291622A1 (en) * | 2004-10-01 | 2006-04-13 | Michel Thiry | Piscirickettsia salmonis antigens and use thereof |
| JP5214464B2 (ja) | 2005-12-28 | 2013-06-19 | アドバンスド バイオニュートリション コーポレーション | 多糖類、糖類およびポリオール類の乾燥マトリックスを含む、ガラス形態の、プロバイオティクス細菌用送達媒体およびその製造方法 |
| DE102007004303A1 (de) * | 2006-08-04 | 2008-02-07 | Osram Opto Semiconductors Gmbh | Dünnfilm-Halbleiterbauelement und Bauelement-Verbund |
| WO2008076975A1 (en) | 2006-12-18 | 2008-06-26 | Advanced Bionutrition Corporation | A dry food product containing live probiotic |
| DE102007004304A1 (de) * | 2007-01-29 | 2008-07-31 | Osram Opto Semiconductors Gmbh | Dünnfilm-Leuchtdioden-Chip und Verfahren zur Herstellung eines Dünnfilm-Leuchtdioden-Chips |
| US20100330113A1 (en) * | 2007-12-19 | 2010-12-30 | Intervet International B.V. | Vaccine Antigens |
| AU2008337440B2 (en) * | 2007-12-19 | 2013-05-02 | Intervet International B.V. | Vaccine antigens from Piscirickettsia salmonis |
| CA2986751A1 (en) * | 2009-03-27 | 2010-09-30 | Intervet International B.V. | Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish |
| JP5841527B2 (ja) | 2009-05-26 | 2016-01-13 | アドバンスド バイオニュートリション コーポレーション | 生物学的に活性な微生物および／または生物活性材料を含む安定な乾燥粉末組成物およびその製造方法 |
| CN102725393B (zh) | 2010-01-28 | 2015-12-02 | 先进生物营养公司 | 包含生物活性材料的干燥玻璃质组合物 |
| US9504750B2 (en) | 2010-01-28 | 2016-11-29 | Advanced Bionutrition Corporation | Stabilizing composition for biological materials |
| NO20100454A1 (no) * | 2010-03-26 | 2011-09-27 | Ewos Innovation As | Forbindelse og sammensetning for kontroll av bakterier og virus |
| SG187250A1 (en) | 2010-08-13 | 2013-03-28 | Advanced Bionutrition Corp | Dry storage stabilizing composition for biological materials |
| US8420072B2 (en) * | 2011-03-24 | 2013-04-16 | The United States Of America, As Represented By The Secretary Of Agriculture | Vaccination of sex reversed hybrid tilapia (Oreochromis niloticus x O. aureus) with an inactivated Vibrio vulnificus vaccine |
| WO2013084169A2 (en) * | 2011-12-07 | 2013-06-13 | Yanez Carcamo Alejandro Javier | Novel broth medium and blood-free solid media for the culture of the fish pathogen piscirickettsia salmonis |
| EP3068426B1 (en) * | 2013-11-13 | 2020-02-12 | University Of Oslo | Outer membrane vesicles and uses thereof |
| DK3328215T3 (da) | 2015-07-29 | 2021-09-13 | Advanced Bionutrition Corp | Stabilt tørre probiotiske sammensætninger til særlige kostanvendelser |
| CL2017003358A1 (es) * | 2017-12-26 | 2018-06-22 | Univ De Chile 50% | Formulación de vacuna para peces en base a nanovesículas lipídicas, en especial, un proteoliposoma o cocleato, con actividad contra el síndrome rickettsial del salmón |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5165925A (en) * | 1989-05-02 | 1992-11-24 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Vaccine for immunizing fish against infectious pancreatic necrosis virus |
| EP0712926B1 (en) | 1994-10-18 | 2003-10-08 | Akzo Nobel N.V. | Fish pancreatic disease virus |
| US20030165526A1 (en) * | 1999-09-17 | 2003-09-04 | Kuzyk Michael A. | Vaccines and agents for inducing immunity against rickettsial diseases, and associated preventative therapy |
| WO2001049712A2 (en) | 2000-01-07 | 2001-07-12 | Akzo Nobel N.V. | Vaccine against isav (infectious salmon anaemia virus) |
| AU2001240791A1 (en) * | 2000-03-11 | 2001-09-24 | Novartis Ag | Sequence |
| WO2002016598A2 (en) * | 2000-08-22 | 2002-02-28 | Agensys, Inc. | Nucleic acid and corresponding protein named 158p1h4 useful in the treatment and detection of bladder and other cancers |
| EP1334197B1 (en) | 2000-11-11 | 2011-01-05 | The University Court of The University of Aberdeen | Yeast derived vaccine against ipnv |
| CA2381708C (en) * | 2001-08-27 | 2011-10-18 | Universidad Catolica De Valparaiso | Immunogenic protein against piscirickettsia salmonis |
-
2004
- 2004-10-01 AT AT04769622T patent/ATE473236T1/de not_active IP Right Cessation
- 2004-10-01 AU AU2004279610A patent/AU2004279610B2/en not_active Ceased
- 2004-10-01 WO PCT/IB2004/003339 patent/WO2005035558A2/en active Application Filing
- 2004-10-01 US US10/574,639 patent/US7754223B2/en active Active
- 2004-10-01 CA CA2541464A patent/CA2541464C/en not_active Expired - Fee Related
- 2004-10-01 EP EP04769622A patent/EP1670818B1/en not_active Not-in-force
- 2004-10-01 DE DE602004028029T patent/DE602004028029D1/de active Active
-
2006
- 2006-05-05 DK DKPA200600643A patent/DK177141B1/da not_active IP Right Cessation
- 2006-05-08 NO NO20062044A patent/NO341223B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK177141B1 (da) | 2012-02-06 |
| NO341223B1 (no) | 2017-09-18 |
| NO20062044L (no) | 2006-07-07 |
| AU2004279610A1 (en) | 2005-04-21 |
| US7754223B2 (en) | 2010-07-13 |
| ATE473236T1 (de) | 2010-07-15 |
| CA2541464C (en) | 2016-02-09 |
| CA2541464A1 (en) | 2005-04-21 |
| EP1670818B1 (en) | 2010-07-07 |
| DE602004028029D1 (en) | 2010-08-19 |
| WO2005035558A3 (en) | 2005-10-13 |
| EP1670818A2 (en) | 2006-06-21 |
| US20070207165A1 (en) | 2007-09-06 |
| AU2004279610B2 (en) | 2010-02-25 |
| WO2005035558A2 (en) | 2005-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK200600643A (da) | Piscirickettsia Salmonis-antigener og anvendelse deraf | |
| Lubroth et al. | Veterinary vaccines and their use in developing countries | |
| Zhugunissov et al. | Goatpox virus (G20-LKV) vaccine strain elicits a protective response in cattle against lumpy skin disease at challenge with lumpy skin disease virulent field strain in a comparative study | |
| Fu et al. | Preparation and evaluation of anti-SARS coronavirus IgY from yolks of immunized SPF chickens | |
| CN109721642B (zh) | 一种i群血清4型-血清8型禽腺病毒二价亚单位疫苗及其制备方法 | |
| Mariappan et al. | Pathological and molecular investigation of velogenic viscerotropic Newcastle disease outbreak in a vaccinated chicken flocks | |
| de Paula et al. | Applied biotechnology for production of immunoglobulin Y specific to hepatitis A virus | |
| Ngichabe et al. | Trial of a capripoxvirus-rinderpest recombinant vaccine in African cattle | |
| Haig | Canine Distemper: Immunisation with Avianised Virus | |
| Li et al. | Oral DNA vaccination with the polyprotein gene of infectious bursal disease virus (IBDV) delivered by attenuated Salmonella elicits protective immune responses in chickens | |
| CN107630024A (zh) | 编码h5亚型禽流感病毒血凝素蛋白的基因及其应用 | |
| Cao et al. | An oral double-targeted DNA vaccine induces systemic and intestinal mucosal immune responses and confers high protection against Vibrio mimicus in grass carps | |
| CN103193869B (zh) | 一种牛口蹄疫病毒a型合成肽及其制备和应用 | |
| CN109136198A (zh) | 一种表达鸡传染性贫血病毒vp1、vp2基因重组鸡痘病毒活载体疫苗 | |
| Zhang et al. | Antibody responses induced by recombinant ALV-A gp85 protein vaccine combining with CpG-ODN adjuvant in breeder hens and the protection for their offspring against early infection | |
| CN104164410B (zh) | 一种鸡新城疫病毒毒株及其在制备鸡新城疫病疫苗中的应用 | |
| CN106031793A (zh) | 一种活疫苗及其制备方法和应用 | |
| Chaffer et al. | Vaccination of turkey poults against pathogenic Escherichia coli | |
| Ronchi et al. | Immunogenicity of two adjuvant formulations of an inactivated African horse sickness vaccine in guinea-pigs and target animals | |
| CN102816741A (zh) | 犬瘟热弱毒疫苗株f和h基因重组新城疫病毒活载体疫苗的构建及其应用 | |
| Barrett et al. | Safety of and humoral immune response to the Merial Recombitek Canine Distemper Virus Vaccine in maned wolves (Chrysocyon brachyurus) | |
| Yilmaz et al. | Approaches to designing of new generation vaccines against the sheep pox disease | |
| DK180291B1 (en) | IgY antibodies for the prevention of sea lice infestation and infection | |
| Rocke et al. | Further development of raccoon poxvirus-vectored vaccines against plague (Yersinia pestis) | |
| RU2659212C1 (ru) | Способ профилактики нодулярного дерматита крупного рогатого скота |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed |
Effective date: 20141031 |